NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Price, News & Analysis $0.15 0.00 (0.00%) (As of 09/16/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Bluejay Diagnostics alerts: Email Address About Bluejay Diagnostics Stock (NASDAQ:BJDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bluejay Diagnostics alerts:Sign Up Key Stats Today's Range$0.14▼$0.1650-Day Range$0.15▼$0.6452-Week Range$0.13▼$48.80Volume1.05 million shsAverage Volume746,826 shsMarket Capitalization$50,433.60P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Read More… Kamala’s Dirty Election Move… Revealed (Ad)According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. Bluejay Diagnostics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 25th PercentileBluejay Diagnostics scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bluejay Diagnostics.Read more about Bluejay Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bluejay Diagnostics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bluejay Diagnostics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBluejay Diagnostics has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bluejay Diagnostics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.01% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently decreased by 34.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBluejay Diagnostics does not currently pay a dividend.Dividend GrowthBluejay Diagnostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.01% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently decreased by 34.98%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.91 News SentimentBluejay Diagnostics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bluejay Diagnostics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for BJDX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders17.60% of the stock of Bluejay Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.47% of the stock of Bluejay Diagnostics is held by institutions.Read more about Bluejay Diagnostics' insider trading history. Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address BJDX Stock News HeadlinesBluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public OfferingJune 28, 2024 | globenewswire.comSYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis PatientsJune 26, 2024 | globenewswire.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 17, 2024 | Behind the Markets (Ad)BJDX: 1Q:24 Financial UpdateMay 24, 2024 | finance.yahoo.comBJDX: 2023 Financial UpdateApril 9, 2024 | finance.yahoo.comBJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023March 29, 2024 | msn.comBluejay Diagnostics Announces Closing of $3.5 Million Public OfferingJanuary 2, 2024 | finance.yahoo.comBluejay Diagnostics Shares Slide Premarket After Stock OfferingDecember 28, 2023 | marketwatch.comSee More Headlines BJDX Stock Analysis - Frequently Asked Questions How have BJDX shares performed this year? Bluejay Diagnostics' stock was trading at $9.76 on January 1st, 2024. Since then, BJDX stock has decreased by 98.5% and is now trading at $0.1501. View the best growth stocks for 2024 here. How were Bluejay Diagnostics' earnings last quarter? Bluejay Diagnostics, Inc. (NASDAQ:BJDX) announced its earnings results on Wednesday, August, 14th. The company reported ($5.12) earnings per share for the quarter. When did Bluejay Diagnostics' stock split? Shares of Bluejay Diagnostics reverse split on Thursday, June 20th 2024. The 1-8 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Bluejay Diagnostics IPO? Bluejay Diagnostics (BJDX) raised $22 million in an IPO on Wednesday, November 10th 2021. The company issued 2,160,000 shares at $10.00 per share. Who are Bluejay Diagnostics' major shareholders? Top institutional shareholders of Bluejay Diagnostics include CVI Holdings LLC (19.69%). Insiders that own company stock include Kenneth R Fisher, Douglas Clark Wurth and Gordon Winston Kinder. View institutional ownership trends. How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today9/16/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:BJDX CUSIPN/A CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($72.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-186.99% Return on Assets-129.49% Debt Debt-to-Equity RatioN/A Current Ratio4.38 Quick Ratio4.38 Sales & Book Value Annual Sales$250,000.00 Price / Sales0.20 Cash FlowN/A Price / Cash FlowN/A Book Value$18.69 per share Price / Book0.01Miscellaneous Outstanding Shares336,000Free Float277,000Market Cap$50,433.60 OptionableNot Optionable Beta0.73 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BJDX) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredFortune: Nexus Technology has “ignited a gold rush”Business Insider estimates it could grow 8,966% in the near future... And Goldman Sachs says it could grow ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.